Close Menu

Beckman Coulter

A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.

The upgrade comes a few weeks after Beckman Coulter issued preliminary 2010 EPS guidance.

GE Healthcare charges in its complaint that kits and instruments sold by Beckman Coulter Genomics based on the Agencourt Solid Phase Reversible Immobilization, or SPRI, technology "contain instructions to use the products in a manner that infringes one or more claims of the '231 and/or '946 patents."

The $6 million first phase of the salmon genome sequencing project will be completed solely with Sanger technology, while the second phase will make use of newer sequencing technologies.

Under a five-year agreement, Beckman Coulter will exclusively distribute CompuCyte's iGeneration technology outside of North America.

The contract is the first of multiple phases to sequence the salmon genome, and is set to be completed and made public by early 2011.

Researchers from Canada, Chile, and Norway will work with Beckman Coulter Genomics to map the Atlantic salmon genome in a $6 million collaboration.

Beckman's revenues were pushed higher on strong recurring revenue and diagnostic sales.

The cuts were due to consolidation of Beckman Coulter's facilities in Orange County, Calif., and its recent acquisition of Olympus' diagnostics business.

Affy said the deal will help fill a gap for customers performing higher-throughput studies by offering access to liquid-handling tools designed to work with its next-generation GeneTitan system and older products.


The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.